Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-4_09-cv-04124/USCOURTS-cand-4_09-cv-04124-32/pdf.json

Nature of Suit Code: 365
Nature of Suit: Personal Injury - Product Liability
Cause of Action: 28:1332 Diversity-Product Liability

---

United States District Court 

For the Northern District of California 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

IN THE UNITED STATES DISTRICT COURT 

FOR THE NORTHERN DISTRICT OF CALIFORNIA 

STEPHEN WENDELL, et al., 

 

 Plaintiffs, 

 

 v. 

JOHNSON & JOHNSON, et al.,

 Defendants. 

________________________________/ 

No. C 09-4124 CW 

ORDER GRANTING IN 

PART MOTION TO 

EXCEED PAGE LIMITS 

(Docket No. 315) 

 

 On December 31, 2013, Defendants Abbott Laboratories, Johnson 

& Johnson, Centocor, Inc., and Teva Pharmaceuticals USA, Inc. 

moved for leave to exceed the page limits for their joint summary 

judgment briefs. Specifically, they seek leave to file an opening 

brief of seventy-five pages and a reply brief of forty-five pages. 

Neither of these requests is justified. 

 Nevertheless, given the number of pharmaceutical products at 

issue in this litigation, the Court will grant Defendants leave to 

file an opening summary judgment brief of up to thirty pages. 

Plaintiff may file a responsive brief of the same length. Because 

Defendants do not yet know how many pages they will need for their 

reply, their request to file a forty-five page reply brief is 

denied. 

IT IS SO ORDERED. 

Dated: CLAUDIA WILKEN 

United States District Judge 

Case 4:09-cv-04124-CW Document 317 Filed 01/06/14 Page 1 of 1